 |
PDBsum entry 2zb4
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Oxidoreductase
|
PDB id
|
|
|
|
2zb4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Oxidoreductase
|
 |
|
Title:
|
 |
Crystal structure of human 15-ketoprostaglandin delta-13-reductase in complex with NADP and 15-keto-pge2
|
|
Structure:
|
 |
Prostaglandin reductase 2. Chain: a. Synonym: ptgr2, 15-oxoprostaglandin 13-reductase, zinc-binding alcohol dehydrogenase domain-containing protein 1. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: ptgr2, zadh1. Expressed in: escherichia coli. Expression_system_taxid: 562.
|
|
Resolution:
|
 |
|
1.63Å
|
R-factor:
|
0.184
|
R-free:
|
0.244
|
|
|
Authors:
|
 |
Y.H.Wu,A.H.J.Wang,T.P.Ko,R.T.Guo,S.M.Hu,L.M.Chuang
|
Key ref:
|
 |
Y.H.Wu
et al.
(2008).
Structural basis for catalytic and inhibitory mechanisms of human prostaglandin reductase PTGR2.
Structure,
16,
1714-1723.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
16-Oct-07
|
Release date:
|
30-Sep-08
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
Q8N8N7
(PTGR2_HUMAN) -
Prostaglandin reductase 2 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
351 a.a.
351 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.1.3.1.48
- 15-oxoprostaglandin 13-reductase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
|
1.
|
13,14-dihydro-15-oxo-prostaglandin E2 + NADP+ = 15-oxoprostaglandin E2 + NADPH + H+
|
|
2.
|
13,14-dihydro-15-oxo-prostaglandin E2 + NAD+ = 15-oxoprostaglandin E2 + NADH + H+
|
|
 |
 |
 |
 |
 |
13,14-dihydro-15-oxo-prostaglandin E2
|
+
|
NADP(+)
Bound ligand (Het Group name = )
corresponds exactly
|
=
|
15-oxoprostaglandin E2
|
+
|
NADPH
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
13,14-dihydro-15-oxo-prostaglandin E2
|
+
|
NAD(+)
Bound ligand (Het Group name = )
matches with 91.67% similarity
|
=
|
15-oxoprostaglandin E2
|
+
|
NADH
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Structure
16:1714-1723
(2008)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural basis for catalytic and inhibitory mechanisms of human prostaglandin reductase PTGR2.
|
|
Y.H.Wu,
T.P.Ko,
R.T.Guo,
S.M.Hu,
L.M.Chuang,
A.H.Wang.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
PTGR2 catalyzes an NADPH-dependent reduction of the conjugated
alpha,beta-unsaturated double bond of 15-keto-PGE(2), a key step in terminal
inactivation of prostaglandins and suppression of PPARgamma-mediated adipocyte
differentiation. Selective inhibition of PTGR2 may contribute to the improvement
of insulin sensitivity with fewer side effects. PTGR2 belongs to the
medium-chain dehydrogenase/reductase superfamily. The crystal structures
reported here reveal features of the NADPH binding-induced conformational change
in a LID motif and a polyproline type II helix which are critical for the
reaction. Mutation of Tyr64 and Tyr259 significantly reduces the rate of
catalysis but increases the affinity to substrate, confirming the structural
observations. Besides targeting cyclooxygenase, indomethacin also inhibits PTGR2
with a binding mode similar to that of 15-keto-PGE(2). The LID motif becomes
highly disordered upon the binding of indomethacin, indicating plasticity of the
active site. This study has implications for the rational design of inhibitors
of PTGR2.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
Figure 2. Structure-Based Sequence Alignment of PTGR2 and
Homologs (A) Stereo view of the crystal structure of the
hPTGR2-NADP^+-15-keto-PGE[2] complex. The nucleotide-binding
domain (H149–Y292) and catalytic domain (M1-G148; K293–L351)
are colored in purple and orange, respectively. The NADP^+
(yellow carbons), 15-keto-PGE[2] (green carbons), and sulfate
ions (dark yellow sulfurs) are shown as ball-and-stick models.
(B) Multiple sequence alignments of human PTGR2 (SwissProt
entry Q8N8N7), mouse PTGR2 (Q3TG36), guinea pig 13-PGR/LTB[4]DH
(Q9EQZ5), and human 13-PGR/LTB[4]DH (A8K0N2). The LID motifs and
PPII helices of PTGR2 are indicated by double-headed arrows. The
conserved nucleotide-binding motif is underlined. Tyr64 and
Tyr259 are marked with red boxes.
|
 |
Figure 6.
Figure 6. Putative Catalytic Residues Alignment of the
active sites of hPTGR2 (cyan), mPTGR2 (magenta), 13-PGR/LTB[4]DH
(yellow), and Etr1p (gray). Hydrogen bonds in PTGR2 and Etr1p
are in red and blue, respectively. Tyr262(B) is from the
countersubunit B of 13-PGR/LTB[4]DH.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Cell Press:
Structure
(2008,
16,
1714-1723)
copyright 2008.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
S.Porté,
A.Moeini,
I.Reche,
N.Shafqat,
U.Oppermann,
J.Farrés,
and
X.Parés
(2011).
Kinetic and structural evidence of the alkenal/one reductase specificity of human ζ-crystallin.
|
| |
Cell Mol Life Sci,
68,
1065-1077.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
');
}
}
 |